Adalimumab, widely recognized by its brand name Humira, is a groundbreaking monoclonal antibody medication developed by Abbott Laboratories (later AbbVie) to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. Discovered in the late 1990s using phage display technology, it became one of the best-selling pharmaceutical blockbuster drugs in global medical history before facing widespread biosimilar competition upon patent expiration.